;PMID: 10392898
;source_file_677.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:46..226] = [t:46..226]
;2)section:[e:230..313] = [t:230..313]
;3)section:[e:317..430] = [t:317..430]
;4)sentence:[e:434..514] = [t:434..514]
;5)sentence:[e:516..650] = [t:516..650]
;6)sentence:[e:651..898] = [t:651..898]
;7)sentence:[e:899..1074] = [t:899..1074]
;8)sentence:[e:1075..1271] = [t:1075..1271]
;9)sentence:[e:1272..1346] = [t:1272..1346]
;10)sentence:[e:1347..1454] = [t:1347..1454]
;11)sentence:[e:1455..1609] = [t:1455..1609]
;12)sentence:[e:1610..1729] = [t:1610..1729]
;13)sentence:[e:1730..1947] = [t:1730..1947]
;14)sentence:[e:1948..2141] = [t:1948..2141]
;15)sentence:[e:2142..2278] = [t:2142..2278]
;16)section:[e:2282..2327] = [t:2282..2327]

;section 0 Span:0..41
;Cell Growth Differ  1999 Jun;10(6):369-76
(SEC
  (FRAG (VBG:[0..4] Cell) (NN:[5..11] Growth) (IN:[12..18] Differ)
        (CD:[20..24] 1999) (.:[25..32] Jun;10-LRB-) (CD:[32..34] 6-RRB-)
        (CD:[34..38] :369) (::[38..39] -) (CD:[39..41] 76)))

;sentence 1 Span:46..226
;Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie 
;T-cell factor/lymphoid enhancer factor transcriptional deregulation in
;gastric  and pancreatic cancer.
;[46..51]...[62..69]:gene-protein:"Beta-"..."catenin"
;[56..69]:gene-protein:"gamma-catenin"
;[89..99]:gene-protein:"E-cadherin"
;[124..137]:gene-protein:"T-cell factor"
;[138..162]:gene-protein:"lymphoid enhancer factor"
;[195..202]...[219..225]:malignancy:"gastric"..."cancer"
;[208..225]:malignancy:"pancreatic cancer"
(SENT
  (S-HLN
    (NP-SBJ
      (NP
        (NP
          (NML (SYM:[46..50] Beta) (HYPH:[50..51] -)
            (NML-1 (-NONE-:[51..51] *P*)))
          (NML-2 (-NONE-:[51..51] *P*)))
        (CC:[52..55] and)
        (NP
          (NML (SYM:[56..61] gamma) (HYPH:[61..62] -)
            (NML-1 (NN:[62..69] catenin)))
          (NML-2 (NNS:[70..79] mutations))))
      (,:[79..80] ,)
      (CONJP (CC:[81..84] but) (RB:[85..88] not))
      (NP (NN:[89..99] E-cadherin) (NN:[100..112] inactivation)))
    (,:[112..113] ,)
    (VP (VBP:[114..122] underlie)
      (NP
        (NML
          (NML (NN:[124..130] T-cell) (NN:[131..137] factor))
          (SYM:[137..138] /)
          (NML
            (NML (JJ:[138..146] lymphoid) (NN:[147..155] enhancer))
            (NN:[156..162] factor)))
        (JJ:[163..178] transcriptional) (NN:[179..191] deregulation))
      (PP (IN:[192..194] in)
        (NP
          (NP (JJ:[195..202] gastric)
            (NML-3 (-NONE-:[202..202] *P*)))
          (CC:[204..207] and)
          (NP (JJ:[208..218] pancreatic)
            (NML-3 (NN:[219..225] cancer))))))
    (.:[225..226] .)))

;section 2 Span:230..313
;Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A, Rimm DL, Costa J,
;Fearon  ER.
(SEC
  (FRAG (NNP:[230..234] Caca) (NNP:[235..236] K) (,:[236..237] ,)
        (NNP:[238..245] Kolligs) (NNP:[246..248] FT) (,:[248..249] ,)
        (NNP:[250..252] Ji) (NNP:[253..254] X) (,:[254..255] ,)
        (NNP:[256..261] Hayes) (NNP:[262..264] M,) (NNP:[265..269] Qian)
        (NNP:[270..272] J,) (NNP:[273..280] Yahanda) (NNP:[281..282] A)
        (,:[282..283] ,) (NNP:[284..288] Rimm) (NNP:[289..291] DL)
        (,:[291..292] ,) (NNP:[293..298] Costa) (NNP:[299..301] J,)
        (NNP:[302..308] Fearon) (NNP:[310..312] ER) (.:[312..313] .)))

;section 3 Span:317..430
;Department of Internal Medicine, The Cancer Center, University of Michigan 
;Medical School, Ann Arbor 48109, USA.
(SEC
  (FRAG (NNP:[317..327] Department) (IN:[328..330] of) (NNP:[331..339] Internal)
        (NNP:[340..348] Medicine) (,:[348..349] ,) (DT:[350..353] The)
        (NNP:[354..360] Cancer) (NNP:[361..367] Center) (,:[367..368] ,)
        (NNP:[369..379] University) (IN:[380..382] of) (NNP:[383..391] Michigan)
        (NNP:[393..400] Medical) (NNP:[401..407] School) (,:[407..408] ,)
        (NNP:[409..412] Ann) (NNP:[413..418] Arbor) (NNP:[419..424] 48109)
        (,:[424..425] ,) (NNP:[426..429] USA) (.:[429..430] .)))

;sentence 4 Span:434..514
;Adenomatous polyposis coli (APC) mutations are present in >70% of colon
;cancers.
;[434..460]:gene-protein:"Adenomatous polyposis coli"
;[462..465]:gene-protein:"APC"
;[500..513]:malignancy:"colon cancers"
(SENT
  (S
    (NP-SBJ
      (NML
        (NML (JJ:[434..445] Adenomatous) (NN:[446..455] polyposis)
             (NN:[456..460] coli))
        (NML (-LRB-:[461..462] -LRB-) (NN:[462..465] APC)
             (-RRB-:[465..466] -RRB-)))
      (NNS:[467..476] mutations))
    (VP (VBP:[477..480] are)
      (ADJP-PRD (JJ:[481..488] present))
      (PP (IN:[489..491] in)
        (NP
          (NP
            (QP (SYM:[492..493] >) (CD:[493..495] 70))
            (NN:[495..496] %))
          (PP (IN:[497..499] of)
            (NP (NN:[500..505] colon) (NNS:[506..513] cancers))))))
    (.:[513..514] .)))

;sentence 5 Span:516..650
;The APC protein binds to beta-catenin (beta-cat), a protein first identified 
;because of its role in E-cadherin (E-cad) cell adhesion.
;[520..523]:gene-protein:"APC"
;[541..553]:gene-protein:"beta-catenin"
;[555..563]:gene-protein:"beta-cat"
;[617..627]:gene-protein:"E-cadherin"
;[629..634]:gene-protein:"E-cad"
(SENT
  (S
    (NP-SBJ (DT:[516..519] The) (NN:[520..523] APC) (NN:[524..531] protein))
    (VP (VBZ:[532..537] binds)
      (PP-CLR (TO:[538..540] to)
        (NP
          (NP
            (NP (NN:[541..553] beta-catenin))
            (NP (-LRB-:[554..555] -LRB-) (NN:[555..563] beta-cat)
                (-RRB-:[563..564] -RRB-)))
          (,:[564..565] ,)
          (NP
            (NP (DT:[566..567] a) (NN:[568..575] protein))
            (VP
              (ADVP (RB:[576..581] first))
              (VBN:[582..592] identified)
              (NP (-NONE-:[592..592] *))
              (PP (IN:[594..601] because) (IN:[602..604] of)
                (NP
                  (NP (PRP$:[605..608] its) (NN:[609..613] role))
                  (PP (IN:[614..616] in)
                    (NP
                      (NML
                        (NML (NN:[617..627] E-cadherin))
                        (NML (-LRB-:[628..629] -LRB-) (NN:[629..634] E-cad)
                             (-RRB-:[634..635] -RRB-)))
                      (NN:[636..640] cell) (NN:[641..649] adhesion))))))))))
    (.:[649..650] .)))

;sentence 6 Span:651..898
;In some colon cancers  lacking APC defects, mutations in presumptive glycogen
;synthase kinase 3beta  phosphorylation sites near the beta-cat NH2 terminus
;appear to render beta-cat  resistant to regulation by APC and glycogen
;synthase kinase 3beta.
;[659..672]:malignancy:"colon cancers"
;[682..685]:gene-protein:"APC"
;[720..750]:gene-protein:"glycogen synthase kinase 3beta"
;[783..791]:gene-protein:"beta-cat"
;[822..830]:gene-protein:"beta-cat"
;[859..862]:gene-protein:"APC"
;[867..897]:gene-protein:"glycogen synthase kinase 3beta"
(SENT
  (S
    (PP (IN:[651..653] In)
      (NP
        (NP (DT:[654..658] some)
           (NN:[659..664] colon) (NNS:[665..672] cancers))
        (VP (VBG:[674..681] lacking)
          (NP (NN:[682..685] APC) (NNS:[686..693] defects)))))
    (,:[693..694] ,)
    (NP-SBJ-1
      (NP (NNS:[695..704] mutations))
      (PP (IN:[705..707] in)
        (NP
          (NP (JJ:[708..719] presumptive)
            (NML (NN:[720..728] glycogen) (NN:[729..737] synthase)
                 (NN:[738..744] kinase) (NN:[745..750] 3beta))
            (NN:[752..767] phosphorylation) (NNS:[768..773] sites))
          (PP-LOC (IN:[774..778] near)
            (NP (DT:[779..782] the) (NN:[783..791] beta-cat) (NN:[792..795] NH2)
                (NN:[796..804] terminus))))))
    (VP (VBP:[805..811] appear)
      (S
        (NP-SBJ-1 (-NONE-:[811..811] *))
        (VP (TO:[812..814] to)
          (VP (VB:[815..821] render)
            (S
              (NP-SBJ (NN:[822..830] beta-cat))
              (ADJP-PRD (JJ:[832..841] resistant)
                (PP (TO:[842..844] to)
                  (NP
                    (NP (NN:[845..855] regulation))
                    (PP (IN:[856..858] by)
                      (NP
                        (NP (NN:[859..862] APC))
                        (CC:[863..866] and)
                        (NP (NN:[867..875] glycogen) (NN:[876..884] synthase)
                            (NN:[885..891] kinase) (NN:[892..897] 3beta))))))))))))
    (.:[897..898] .)))

;sentence 7 Span:899..1074
;In cells with  APC or beta-cat defects, beta-cat is stabilized and, in turn,
;binds to and  activates T-cell factor (Tcf)/lymphoid enhancer factor (Lef)
;transcription  factors.
;[914..917]:gene-protein:"APC"
;[921..929]:gene-protein:"beta-cat"
;[939..947]:gene-protein:"beta-cat"
;[1000..1013]:gene-protein:"T-cell factor"
;[1015..1018]:gene-protein:"Tcf"
;[1020..1044]:gene-protein:"lymphoid enhancer factor"
;[1046..1049]:gene-protein:"Lef"
(SENT
  (S
    (PP-LOC (IN:[899..901] In)
      (NP
        (NP (NNS:[902..907] cells))
        (PP (IN:[908..912] with)
          (NP
            (NP (NN:[914..917] APC)
              (NML-1 (-NONE-:[917..917] *P*)))
            (CC:[918..920] or)
            (NP (NN:[921..929] beta-cat)
              (NML-1 (NNS:[930..937] defects)))))))
    (,:[937..938] ,)
    (NP-SBJ-2 (NN:[939..947] beta-cat))
    (VP
      (VP (VBZ:[948..950] is)
        (VP (VBN:[951..961] stabilized)
          (NP-2 (-NONE-:[961..961] *))))
      (CC:[962..965] and) (,:[965..966] ,)
      (VP
        (PP (IN:[967..969] in)
          (NP (NN:[970..974] turn)))
        (,:[974..975] ,)
        (VP (VBZ:[976..981] binds)
          (PP-CLR (TO:[982..984] to)
            (NP-3 (-NONE-:[984..984] *RNR*))))
        (CC:[985..988] and)
        (VP (VBZ:[990..999] activates)
          (NP-3 (-NONE-:[999..999] *RNR*)))
        (NP-3
          (NML
            (NML
              (NML (NN:[1000..1006] T-cell) (NN:[1007..1013] factor))
              (NML (-LRB-:[1014..1015] -LRB-) (NN:[1015..1018] Tcf)
                   (-RRB-:[1018..1019] -RRB-)))
            (SYM:[1019..1020] /)
            (NML
              (NML
                (NML (JJ:[1020..1028] lymphoid) (NN:[1029..1037] enhancer))
                (NN:[1038..1044] factor))
              (NML (-LRB-:[1045..1046] -LRB-) (NN:[1046..1049] Lef)
                   (-RRB-:[1049..1050] -RRB-))))
          (NN:[1051..1064] transcription) (NNS:[1066..1073] factors))))
    (.:[1073..1074] .)))

;sentence 8 Span:1075..1271
;To further explore the role of APC, beta-cat, Tcf, and E-cad defects in 
;gastrointestinal cancers, we assessed gastric and pancreatic cancers for 
;constitutive Tcf transcriptional activity (CTTA).
;[1106..1109]:gene-protein:"APC"
;[1111..1119]:gene-protein:"beta-cat"
;[1121..1124]:gene-protein:"Tcf"
;[1130..1135]:gene-protein:"E-cad"
;[1148..1172]:malignancy:"gastrointestinal cancers"
;[1186..1193]...[1209..1216]:malignancy:"gastric"..."cancers"
;[1198..1216]:malignancy:"pancreatic cancers"
;[1235..1238]:gene-protein:"Tcf"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1075..1075] *))
      (VP (TO:[1075..1077] To)
        (ADVP (RBR:[1078..1085] further))
        (VP (VB:[1086..1093] explore)
          (NP
            (NP (DT:[1094..1097] the) (NN:[1098..1102] role))
            (PP (IN:[1103..1105] of)
              (NP
                (NP (NN:[1106..1109] APC)
                  (NML-2 (-NONE-:[1109..1109] *P*)))
                (,:[1109..1110] ,)
                (NP (NN:[1111..1119] beta-cat)
                  (NML-2 (-NONE-:[1119..1119] *P*)))
                (,:[1119..1120] ,)
                (NP (NN:[1121..1124] Tcf)
                  (NML-2 (-NONE-:[1124..1124] *P*)))
                (,:[1124..1125] ,) (CC:[1126..1129] and)
                (NP (NN:[1130..1135] E-cad)
                  (NML-2 (NNS:[1136..1143] defects))))))
          (PP (IN:[1144..1146] in)
            (NP (JJ:[1148..1164] gastrointestinal) (NNS:[1165..1172] cancers))))))
    (,:[1172..1173] ,)
    (NP-SBJ (PRP:[1174..1176] we))
    (VP (VBD:[1177..1185] assessed)
      (NP
        (NP (JJ:[1186..1193] gastric)
          (NML-1 (-NONE-:[1193..1193] *P*)))
        (CC:[1194..1197] and)
        (NP (JJ:[1198..1208] pancreatic)
          (NML-1 (NNS:[1209..1216] cancers))))
      (PP-PRD (IN:[1217..1220] for)
        (NP
          (NP (JJ:[1222..1234] constitutive) (NN:[1235..1238] Tcf)
              (JJ:[1239..1254] transcriptional) (NN:[1255..1263] activity))
          (NP (-LRB-:[1264..1265] -LRB-) (NN:[1265..1269] CTTA)
              (-RRB-:[1269..1270] -RRB-)))))
    (.:[1270..1271] .)))

;sentence 9 Span:1272..1346
;Two of four gastric and two of  eight pancreatic cancer lines showed CTTA.
;[1284..1291]...[1321..1327]:malignancy:"gastric"..."cancer"
;[1310..1327]:malignancy:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (CD:[1272..1275] Two))
        (PP (IN:[1276..1278] of)
          (NP (CD:[1279..1283] four) (JJ:[1284..1291] gastric)
            (NML-1 (-NONE-:[1291..1291] *RNR*)))))
      (CC:[1292..1295] and)
      (NP
        (NP (CD:[1296..1299] two))
        (PP (IN:[1300..1302] of)
          (NP (CD:[1304..1309] eight) (JJ:[1310..1320] pancreatic)
            (NML-1 (-NONE-:[1320..1320] *RNR*)))))
      (NML-1 (NN:[1321..1327] cancer) (NNS:[1328..1333] lines)))
    (VP (VBD:[1334..1340] showed)
      (NP (NN:[1341..1345] CTTA)))
    (.:[1345..1346] .)))

;sentence 10 Span:1347..1454
;One gastric and one pancreatic cancer  had mutations in the NH2-terminal
;phosphorylation sites of beta-cat.
;[1351..1358]...[1378..1384]:malignancy:"gastric"..."cancer"
;[1367..1384]:malignancy:"pancreatic cancer"
;[1445..1453]:gene-protein:"beta-cat"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1347..1350] One) (JJ:[1351..1358] gastric)
        (NML-1 (-NONE-:[1358..1358] *P*)))
      (CC:[1359..1362] and)
      (NP (CD:[1363..1366] one)
         (JJ:[1367..1377] pancreatic)
        (NML-1 (NN:[1378..1384] cancer))))
    (VP (VBD:[1386..1389] had)
      (NP
        (NP (NNS:[1390..1399] mutations))
        (PP-LOC (IN:[1400..1402] in)
          (NP
            (NP (DT:[1403..1406] the)
              (NML (NN:[1407..1410] NH2) (HYPH:[1410..1411] -)
                   (JJ:[1411..1419] terminal))
              (NN:[1420..1435] phosphorylation) (NNS:[1436..1441] sites))
            (PP (IN:[1442..1444] of)
              (NP (NN:[1445..1453] beta-cat)))))))
    (.:[1453..1454] .)))

;sentence 11 Span:1455..1609
;The other  gastric cancer with CTTA had a missense mutation at serine 28 of
;gamma-cat, a  potential phosphorylation site in this beta-cat-related
;protein.
;[1466..1480]:malignancy:"gastric cancer"
;[1497..1514]:variation-type:"missense mutation"
;[1518..1524]:variation-state-original:"serine"
;[1525..1527]:variation-location:"28"
;[1531..1540]:gene-protein:"gamma-cat"
;[1584..1592]:gene-protein:"beta-cat"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1455..1458] The) (JJ:[1459..1464] other)
         (JJ:[1466..1473] gastric) (NN:[1474..1480] cancer))
      (PP (IN:[1481..1485] with)
        (NP (NN:[1486..1490] CTTA))))
    (VP (VBD:[1491..1494] had)
      (NP
        (NP (DT:[1495..1496] a)
           (JJ:[1497..1505] missense) (NN:[1506..1514] mutation))
        (PP-LOC (IN:[1515..1517] at)
          (NP
            (NP
              (NP (NN:[1518..1524] serine) (CD:[1525..1527] 28))
              (PP (IN:[1528..1530] of)
                (NP (NN:[1531..1540] gamma-cat))))
            (,:[1540..1541] ,)
            (NP
              (NP (DT:[1542..1543] a) (JJ:[1545..1554] potential)
                  (NN:[1555..1570] phosphorylation) (NN:[1571..1575] site))
              (PP (IN:[1576..1578] in)
                (NP (DT:[1579..1583] this)
                  (ADJP (NN:[1584..1592] beta-cat) (HYPH:[1592..1593] -)
                        (VBN:[1593..1600] related))
                  (NN:[1601..1608] protein))))))))
    (.:[1608..1609] .)))

;sentence 12 Span:1610..1729
;Although E-cad  is an important binding partner for beta-cat and gamma-cat,
;E-cad inactivation  did not result in CTTA.
;[1619..1624]:gene-protein:"E-cad"
;[1662..1670]:gene-protein:"beta-cat"
;[1675..1684]:gene-protein:"gamma-cat"
;[1686..1691]:gene-protein:"E-cad"
(SENT
  (S
    (SBAR-ADV (IN:[1610..1618] Although)
      (S
        (NP-SBJ (NN:[1619..1624] E-cad))
        (VP (VBZ:[1626..1628] is)
          (NP-PRD (DT:[1629..1631] an) (JJ:[1632..1641] important)
                  (VBG:[1642..1649] binding) (NN:[1650..1657] partner))
          (PP (IN:[1658..1661] for)
            (NP (NN:[1662..1670] beta-cat) (CC:[1671..1674] and)
                (NN:[1675..1684] gamma-cat))))))
    (,:[1684..1685] ,)
    (NP-SBJ (NN:[1686..1691] E-cad) (NN:[1692..1704] inactivation))
    (VP (VBD:[1706..1709] did) (RB:[1710..1713] not)
      (VP (VB:[1714..1720] result)
        (PP-CLR (IN:[1721..1723] in)
          (NP (NN:[1724..1728] CTTA)))))
    (.:[1728..1729] .)))

;sentence 13 Span:1730..1947
;The beta-cat and gamma-cat mutant proteins identified in  our studies
;strongly activated Tcf transcription in vitro, whereas beta-cat  mutant
;proteins with large NH2-terminal deletions had only modest effects on  Tcf.
;[1734..1742]:gene-protein:"beta-cat"
;[1747..1756]:gene-protein:"gamma-cat"
;[1819..1822]:gene-protein:"Tcf"
;[1855..1863]:gene-protein:"beta-cat"
;[1905..1914]:variation-type:"deletions"
;[1943..1946]:gene-protein:"Tcf"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1730..1733] The)
        (NML
          (NML (NN:[1734..1742] beta-cat)
            (NML-1 (-NONE-:[1742..1742] *P*)))
          (CC:[1743..1746] and)
          (NML (NN:[1747..1756] gamma-cat)
            (NML-1 (JJ:[1757..1763] mutant) (NNS:[1764..1772] proteins)))))
      (VP (VBN:[1773..1783] identified)
        (NP (-NONE-:[1783..1783] *))
        (PP (IN:[1784..1786] in)
          (NP (PRP$:[1788..1791] our) (NNS:[1792..1799] studies)))))
    (ADVP (RB:[1800..1808] strongly))
    (VP (VBD:[1809..1818] activated)
      (NP (NN:[1819..1822] Tcf) (NN:[1823..1836] transcription))
      (ADVP (FW:[1837..1839] in) (FW:[1840..1845] vitro))
      (,:[1845..1846] ,)
      (SBAR-ADV (IN:[1847..1854] whereas)
        (S
          (NP-SBJ
            (NP (NN:[1855..1863] beta-cat) (JJ:[1865..1871] mutant)
                (NNS:[1872..1880] proteins))
            (PP (IN:[1881..1885] with)
              (NP (JJ:[1886..1891] large)
                (NML (NN:[1892..1895] NH2) (HYPH:[1895..1896] -)
                     (JJ:[1896..1904] terminal))
                (NNS:[1905..1914] deletions))))
          (VP (VBD:[1915..1918] had)
            (NP
              (NP (RB:[1919..1923] only) (JJ:[1924..1930] modest)
                  (NNS:[1931..1938] effects))
              (PP (IN:[1939..1941] on)
                (NP (NN:[1943..1946] Tcf))))))))
    (.:[1946..1947] .)))

;sentence 14 Span:1948..2141
;Our results suggest a role for Tcf deregulation in gastric and pancreatic 
;cancer, resulting from beta-cat and gamma-cat mutations in some cases and, in
; others, from yet to be defined defects.
;[1979..1982]:gene-protein:"Tcf"
;[1999..2006]...[2023..2029]:malignancy:"gastric"..."cancer"
;[2011..2029]:malignancy:"pancreatic  cancer"
;[2046..2054]:gene-protein:"beta-cat"
;[2059..2068]:gene-protein:"gamma-cat"
(SENT
  (S
    (NP-SBJ (PRP$:[1948..1951] Our) (NNS:[1952..1959] results))
    (VP (VBP:[1960..1967] suggest)
      (NP
        (NP
          (NP (DT:[1968..1969] a) (NN:[1970..1974] role))
          (PP (IN:[1975..1978] for)
            (NP (NN:[1979..1982] Tcf) (NN:[1983..1995] deregulation)))
          (PP (IN:[1996..1998] in)
            (NP
              (NP (JJ:[1999..2006] gastric)
                (NML-1 (-NONE-:[2006..2006] *P*)))
              (CC:[2007..2010] and)
              (NP (JJ:[2011..2021] pancreatic)
                (NML-1 (NN:[2023..2029] cancer))))))
        (,:[2029..2030] ,)
        (VP
          (VP (VBG:[2031..2040] resulting)
            (PP=4 (IN:[2041..2045] from)
              (NP
                (NP (NN:[2046..2054] beta-cat)
                  (NML-2 (-NONE-:[2054..2054] *P*)))
                (CC:[2055..2058] and)
                (NP (NN:[2059..2068] gamma-cat)
                  (NML-2 (NNS:[2069..2078] mutations)))))
            (PP=5 (IN:[2079..2081] in)
              (NP (DT:[2082..2086] some) (NNS:[2087..2092] cases))))
          (CC:[2093..2096] and) (,:[2096..2097] ,)
          (VP
            (PP=5 (IN:[2098..2100] in)
              (NP (NNS:[2102..2108] others)))
            (,:[2108..2109] ,)
            (PP=4 (IN:[2110..2114] from)
              (NP
                (NML
                  (S
                    (NP-SBJ-3 (-NONE-:[2114..2114] *))
                    (ADVP (RB:[2115..2118] yet))
                    (VP (TO:[2119..2121] to)
                      (VP (VB:[2122..2124] be)
                        (VP (VBN:[2125..2132] defined)
                          (NP-3 (-NONE-:[2132..2132] *)))))))
                (NNS:[2133..2140] defects)))))))
    (.:[2140..2141] .)))

;sentence 15 Span:2142..2278
;Furthermore, these data imply that the  consequences of APC and beta-cat
;mutations are distinct from the effects of  E-cad inactivation.
;[2198..2201]:gene-protein:"APC"
;[2206..2214]:gene-protein:"beta-cat"
;[2259..2264]:gene-protein:"E-cad"
(SENT
  (S
    (ADVP (RB:[2142..2153] Furthermore))
    (,:[2153..2154] ,)
    (NP-SBJ (DT:[2155..2160] these) (NNS:[2161..2165] data))
    (VP (VBP:[2166..2171] imply)
      (SBAR (IN:[2172..2176] that)
        (S
          (NP-SBJ
            (NP (DT:[2177..2180] the) (NNS:[2182..2194] consequences))
            (PP (IN:[2195..2197] of)
              (NP
                (NP (NN:[2198..2201] APC)
                  (NML-1 (-NONE-:[2201..2201] *P*)))
                (CC:[2202..2205] and)
                (NP (NN:[2206..2214] beta-cat)
                  (NML-1 (NNS:[2215..2224] mutations))))))
          (VP (VBP:[2225..2228] are)
            (ADJP-PRD (JJ:[2229..2237] distinct)
              (PP (IN:[2238..2242] from)
                (NP
                  (NP (DT:[2243..2246] the) (NNS:[2247..2254] effects))
                  (PP (IN:[2255..2257] of)
                    (NP (NN:[2259..2264] E-cad) (NN:[2265..2277] inactivation))))))))))
    (.:[2277..2278] .)))

;section 16 Span:2282..2327
;PMID: 10392898 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2282..2286] PMID) (::[2286..2287] :) (CD:[2288..2296] 10392898)
        (NN:[2297..2298] -LSB-) (NNP:[2298..2304] PubMed) (::[2305..2306] -)
        (NN:[2307..2314] indexed) (IN:[2315..2318] for)
        (NNP:[2319..2327] MEDLINE-RSB-)))
